CAR-T manufacturing process and the supply chain behind it

micheal-eder

Michael Eder

June 23, 2022

Table of contents

Show

Mastering the complex CAR T manufacturing process and the associated supply chain challenges in the cell and gene area are the major bottlenecks during the large-scale commercialization of highly promising CAR T cell products. 


 This autologous transgene cellular therapy approach has gained US Food and Drug Administration (FDA) approval for relapsed or refractory blood malignancies such as B cell acute lymphoblastic leukemia (ALL) and diffuse large B cell lymphoma (DLBCL), in the instance of Novartis’ Kymriah, which was developed in collaboration with the University of Pennsylvania. Numerous clinical trials are currently ongoing to ascertain whether additional indications could benefit from CAR T cell cancer immunotherapy.1 2 3 

CAR T manufacturing process

The CAR T manufacturing process is a very sensitive and highly complex endeavor. In brief, the patient’s T lymphocytes are removed from the bloodstream and reprogrammed in the laboratory to become very alert and aggressive towards cancer cells through expression of chimeric antigen receptors, resulting in very effective antitumor drugs.


Due to the intricacies of the human immune system, each patient needs an individualized batch of chimeric antigen receptor T cells, implying that these are no off-the-shelf drugs. Each batch of CAR T cells is a distinct manufacturing campaign with its own supply chain that begins at the patient.

Personalized supply chain for CAR T cell therapy

The power of CAR-T therapy lies in the fact that every therapy is tailored to meet each individual patient's needs. The flip side of the coin is the complex supply chain situation this implies: Every patient contributes source material that has to be shipped under cryogenic and aseptic conditions to the manufacturing facility in order to manufacture one distinct batch of extremely valuable, unique drug substance. 

Any faults along the supply chain may lead to severe consequences for the patient. Therefore, biopharmaceutical companies undertake great efforts to eliminate failure modes wherever possible and minimize all conceivable risks of the process.

Collection of CAR T cells from the patient

The first step in most CAR T cell manufacturing processes is the collection of T cells from the respective patients. This is done in a procedure named leukapheresis. Generally, apheresis is the removal of blood cells from peripheral blood, leukapheresis is the collection of leukocytes. Instruments such as CliniMACS Plus and Prodigy allow the isolation of specific subtypes of T cells. 

Chemotherapy cycles that are performed prior to leukapheresis have been shown to reduce the viability of T cells and experts in oncology advise the early collection of T cells, prior to stem-cell transplants.


With the leukapheresis process, the individualized supply chain commences.4 5 

Transportation of the collected T-cells to the lab

Next, the collected T cells are prepared for the transport from the healthcare site to the manufacturing facilities. In order to keep the cells viable, they are transferred into single use bags, which in turn are placed into protective shells and subsequently frozen, shipped and stored at ultra-cold temperatures (cryopreservation).

App Note: "Bestcellers": Controlled Filling & Freezing of Cells

"Bestcellers": Controlled Filling & Freezing of Cells Advanced Fluid Management for Cell Culture, Freezing, Cell Banking and Cell Therapy

Development of individualized CAR T-cells

At the cell therapy manufacturing site, the CAR T cells are thawed for modification. The next step is viral transduction and involves the actual gene transfer into T cells using viral vectors such as lentiviral vectors. This exposure to reprogramming lentivirus leads to genetic modification of the TCRs of the cells, resulting in anti-CD19 CAR T cell activation towards tumor cells. 

Next, ex vivo proliferation of CAR T cells is performed in cell culture in bioreactors (CAR T cell expansion) to obtain sufficient amounts of the biopharmaceutical material. Since this workflow is adherent to good manufacturing practice (GMP), numerous testings, characterizations and quality control measures are performed on the CAR T cells to ensure full satisfaction of all regulatory requirements. These requirements include the absence of mycoplasma, minimal variability of phenotypes and cell types, low endotoxin mediated toxicity and many more.6 

Transportation of CAR T cells from the lab to the patient

When the individualized CAR T cell immunotherapy product has passed all tests, the cells are again packaged in medical devices, put into their protective sleeves and brought to cryogenic temperatures for transportation to the medical center. Orchestration of all participants is very important to ensure timely delivery and appropriate storage conditions before the product is administered to the patient.

Car t-cell therapy - How does it work?

Considerations for a safe supply chain

In order to set up safe supply chains, a complex network of interdependent variables must be orchestrated:

  • schedules of patients, healthcare providers, manufacturing facilities
  • demand volatility
  • cost optimization
  • patient safety and security

The ultimate goal is an efficient end-to-end collaboration of all participants. Innovative products that support real-time tracking of processes and data analysis using cloud computing offers powerful digital solutions to the supply chain problem.

Single Use Support’s part in CAR T manufacturing process and supply chain

Single Use Support offers a comprehensive product portfolio that facilitates the development and upscaling of CAR T manufacturing processes. Moreover, its products are highly compatible in order to enable a smooth workflow along the complex vein-to-vein supply chain. For instance, RFID tags on every component take care of automation regarding the real-time documentation of passing checkpoints during handling, transfer volumes, temperatures, and gapless recording of the chain of identity of each batch.

Single-use components lead to more efficient use of space at manufacturing sites, facilitate scalable operations, e.g. with the Single Use Support freeze-thaw-platforms, and offer end-to-end process solutions for cell and gene therapies. 

  1. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia, http://dx.doi.org/10.1056/NEJMoa1407222, Published 2014-10-15
  2. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies, http://dx.doi.org/10.1158/2326-6066.CIR-13-0170, Published 2013-12-20
  3. Mechanisms of resistance to CAR T cell therapy, http://dx.doi.org/10.1038/s41571-019-0184-6, Published 2019-03-05
  4. , Published 1970-01-01
  5. Apheresis Techniques and Cellular Immunomodulation, http://dx.doi.org/10.1111/j.1744-9987.1997.tb00137.x, Published 2007-11-14
  6. Genetically modified T cells in cancer therapy: opportunities and challenges, http://dx.doi.org/10.1242/dmm.018036, Published 2015-04-01
micheal-eder

Michael Eder

Senior Marketing Manager

Michael Eder, MA, is Senior Marketing Manager at Single Use Support. He is expert in pharma and health communication with his 8+ years experience in pharma. After completing his master's degree in International Healthcare Management at MCI The Entrepreneurial school in Innsbruck, he has gained experience in the pharmaceutical field. Michael creates articles about Freeze Thaw applications and Platform solutions from Single Use Support and is the author of current news with Single Use Support worldwide. 

More from Michael Eder

Vaccines

The development process of biosimilars

The development process of biosimilars slightly differs from the one of their reference biologics. In this article, we will discuss each phase in detail.

micheal-eder

Michael Eder

May 13, 2024

Vaccines

Biomanufacturing: Process, steps and challenges in manufacturing biologics

As biologics have become a central pillar in today’s healthcare sector, their manufacturing process increasingly draws attention. In this article, we will discuss the process step by step, including challenges and possible ways to overcome them.

micheal-eder

Michael Eder

May 13, 2024

Read more about Cell & Gene Therapy

Cell & Gene Therapy

Study: Optimizing Cell Viability During CHO Cell Freezing

In a recent study, freezing protocols were tested with the RoSS.LN2F controlled liquid nitrogen freezer to find the optimal freezing rate for CHO-K1 cells in order to achieve maximum cell viability. 

Alexander Fuchs | Single Use Support

Alexander Fuchs

February 16, 2024

Cell & Gene Therapy

Regulations for Cryoprotectants in ATMP Cryopreservation

Adequate quality control samples retained before cell therapy treatment are a crucial component of effective regulation and need to represent the conditions and history in the cryobag. A deep dive into GMP Annex 1 on ATMP Cryopreservation.

Khalil Essani - Single Use Support

Khalil Essani

February 7, 2024

Cell & Gene Therapy

Stressing Cells: The Role of Cryoprotectants in ATMP Cryopreservation

The objective of an optimal cryopreservation strategy is to deactivate (put on hold) degenerative cellular pathways and preserve proliferative potential by reducing the temperature below –130°C. To reduce the effects of ice crystal and osmotic injuries, cryopreservation protocols usually incorporate cryoprotective agents (CPAs).

Khalil Essani - Single Use Support

Khalil Essani

February 8, 2024

Cell & Gene Therapy

Optimizing pDNA production using advanced single-use technologies

Considering the widespread need for efficient pDNA production, the industry is seeking to improve the current manufacturing process. In this article, we will discover how single-use technologies can contribute to pDNA manufacturing optimizations.

Khalil Essani - Single Use Support

Khalil Essani

November 10, 2023